Resultats globals: 3 registres trobats en 0.04 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
10 p, 1.8 MB Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma : Updated Overall Survival, Safety, and Subgroups / Orlowski, R.Z. (Department of Lymphoma and Myeloma. The University of Texas M.D. Anderson Cancer Center) ; Moreau, P. (Department of Hematology. University Hospital Hotel-Dieu) ; Niesvizky, R. (Department of Medical Oncology. Myeloma Center. New York Presbyterian Hospital-Weill Cornell Medical Center) ; Ludwig, H. (Department of Medicine I. Wilhelminen Cancer Research Institute. Wilhelminenspital) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Chng, W.J. (Department of Hematology Oncology. National University of Singapore) ; Goldschmidt, H. (Department of Hematology Oncology. Heidelberg University Clinic and the National Center of Tumor Diseases) ; Yang, Z. (Department of Biostatistics. Amgen. Inc) ; Kimball, A.S. (Department of Clinical Research. Amgen. Inc) ; Dimopoulos, M. (Department of Clinical Therapeutics. University Athens School of Medicine) ; Universitat Autònoma de Barcelona
Introduction: The phase III RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial showed significantly improved progression-free survival and overall survival (OS) with carfilzomib (56 mg/m) and dexamethasone (Kd56) versus bortezomib and Kd56 (Vd) in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2019 - 10.1016/j.clml.2019.04.018
Clinical Lymphoma, Myeloma and Leukemia, Vol. 19 Núm. 8 (august 2019) , p. 522-530.e1  
2.
11 p, 1.4 MB Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma : an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials / Weisel, K. (Department of Hematology. Oncology. Immunology. Rheumatology. and Pulmonology. Medical Clinic II) ; Majer, I. (Amgen Europe GmbH) ; DeCosta, L. (Amgen Ltd) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Goldschmidt, H. (Internal Medicine V and National Center of Tumor Diseases. University Clinic Heidelberg) ; Ludwig, H. (Wilhelminen Cancer Research Institute. Wilhelminenspital) ; Campioni, M. (Amgen Europe GmbH) ; Szabo, Z. (Amgen Europe GmbH) ; Dimopoulos, M. (School of Medicine. National and Kapodistrian University of Athens. Alexandra Hospital) ; Universitat Autònoma de Barcelona
In ENDEAVOR, carfilzomib and dexamethasone (Kd56) demonstrated significant improvement in progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd). Both agents were administered until disease progression; the EU label for Vd, however, stipulates a maximum of eight treatment cycles. [...]
2020 - 10.1080/10428194.2019.1648806
Leukemia and Lymphoma, Vol. 61 Núm. 1 (february 2020) , p. 37-46  
3.
8 p, 788.7 KB A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) / Hájek, R. (University Hospital Ostrava) ; Masszi, T (St István and St László Hospital of Budapest) ; Petrucci,M.T. (Sapienza Università di Roma) ; Palumbo, A. (Università di Torino) ; Rosiñol, L. (Hospital Clínic i Provincial de Barcelona) ; Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ; Yong, K.L. (University College London Cancer Institute) ; Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Minarik, J. (University Hospital Olomouc and Medical Faculty of Palacky) ; Pour, L (University Hospital Ostrava) ; Dimopoulos, M.A. (National and Kapodistrian University of Athens) ; Maisnar, V. (Charles University Teaching Hospital, Hradec Králové) ; Rossi, D. (Amedeo Avogadro University of Eastern Piedmont) ; Kasparu, H. (Hospital Elisabethinen Linz) ; Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ; Yehuda, D.B. (Hadassah Medical Center, Jerusalem, Israel) ; Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ; Jenner, M. (Southampton General Hospital, Hampshire, UK) ; Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ; Dávid, M. (University of Pécs, Hungary) ; de la Rubia, J. (Hospital Universitario La Fe, València) ; Drach, J. (Medical University of Vienna) ; Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ; Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ; Leleu, X. (Hopital Huriez, CHRU, Lille, France) ; Munder, M. (University Medicine Mainz, Germany) ; Offidani, M (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ; Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ; Rajangam, K. (Onyx Pharmaceuticals, Inc.) ; Chang, Y.L. (Onyx Pharmaceuticals, Inc.) ; San-Miguel, J.F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Ludwig, H. (Wilhelminen Cancer Research Institute, Vienna, Austria)
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.